First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
about
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
First-in human, phase 1, dose- ...... ced solid tumors (SAKK 67/13).
@en
First-in human, phase 1, dose- ...... ced solid tumors (SAKK 67/13).
@nl
type
label
First-in human, phase 1, dose- ...... ced solid tumors (SAKK 67/13).
@en
First-in human, phase 1, dose- ...... ced solid tumors (SAKK 67/13).
@nl
prefLabel
First-in human, phase 1, dose- ...... ced solid tumors (SAKK 67/13).
@en
First-in human, phase 1, dose- ...... ced solid tumors (SAKK 67/13).
@nl
P2093
P1476
First-in human, phase 1, dose- ...... nced solid tumors (SAKK 67/13)
@en
P2093
Alexa Childs
Alexandros Xyrafas
Cinta Hierro
Cristiana Sessa
Dagmar Hess
Hanne Hawle
Jordi Rodon
Markus Joerger
Michael Stumm
Nataša Cmiljanović
P356
10.1016/J.EJCA.2018.03.012
P577
2018-04-13T00:00:00Z